FGI-103

FGI-103
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 2-[(E)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-3H-benzimidazole-5-carboximidamide;
CAS Number	907169-69-1 ;
PubChem CID	5477931;
ChemSpider	4585571;
Chemical and physical data
Formula	C19H16N6O
Molar mass	344.369 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N=C(N)c4ccc3oc(C=Cc2nc1cc(C(=N)N)ccc1[nH]2)cc3c4;
	InChI InChI=1S/C19H16N6O/c20-18(21)10-2-5-16-12(7-10)8-13(26-16)3-6-17-24-14-4-1-11(19(22)23)9-15(14)25-17/h1-9H,(H3,20,21)(H3,22,23)(H,24,25)/b6-3+; Key:OOKWWPFCCCMWIS-ZZXKWVIFSA-N;

FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.^[1]^[2]^[3]

References

^ Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A. S.; Kinch, M. S.; Goldblatt, M.; Aman, M. J.; Bavari, S. (2010). "Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection". Antimicrobial Agents and Chemotherapy. 54 (5): 2152–9. doi:10.1128/AAC.01315-09. PMC 2863630. PMID 20211898.
^ Bradfute, S. B.; Warfield, K. L.; Bray, M. (2012). "Mouse Models for Filovirus Infections". Viruses. 4 (12): 1477–1508. doi:10.3390/v4091477.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology 1 January 2015, 93(1):1–10. doi:10.1016/j.bcp.2014.11.008

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A. S.; Kinch, M. S.; Goldblatt, M.; Aman, M. J.; Bavari, S. (2010). "Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection". Antimicrobial Agents and Chemotherapy. 54 (5): 2152–9. doi:10.1128/AAC.01315-09. PMC 2863630. PMID 20211898.

[2] Bradfute, S. B.; Warfield, K. L.; Bray, M. (2012). "Mouse Models for Filovirus Infections". Viruses. 4 (12): 1477–1508. doi:10.3390/v4091477.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[3] De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology 1 January 2015, 93(1):1–10. doi:10.1016/j.bcp.2014.11.008

[1]

[2]

[3]

See also

References